• Publications
  • Influence
Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.
BACKGROUND The aim of this systematic review was to summarise and appraise the published evidence with regard to the frequency and risk factors of subclinical cardiotoxicity in apparently healthyExpand
  • 290
  • 10
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
PURPOSE Anthracycline-induced cardiotoxicity (ACT) is a serious adverse drug reaction limiting anthracycline use and causing substantial morbidity and mortality. Our aim was to identify geneticExpand
  • 263
  • 10
Cardioprotective interventions for cancer patients receiving anthracyclines.
BACKGROUND Anthracyclines are among the most effective chemotherapeutic agents in the treatment of numerous malignancies. Unfortunately, their use is limited by a dose-dependent cardiotoxicity. In anExpand
  • 187
  • 10
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
Survivors of childhood cancer treated with anthracycline chemotherapy or chest radiation are at an increased risk of developing congestive heart failure. In this population, congestive heart failureExpand
  • 238
  • 8
A Coding Variant in RARG Confers Susceptibility to Anthracycline-Induced Cardiotoxicity in Childhood Cancer
Anthracyclines are used in over 50% of childhood cancer treatment protocols, but their clinical usefulness is limited by anthracycline-induced cardiotoxicity (ACT) manifesting as asymptomatic cardiacExpand
  • 126
  • 7
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children
. The use of anthracyclines as effective antineoplastic drugs is limited by the occurrence of cardiotoxicity. Multiple genetic variants predictive of anthracycline‐induced cardiotoxicity (ACT) inExpand
  • 95
  • 7
Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
The cumulative incidence of anthracycline-induced clinical heart failure (A-CHF) in a large cohort of 830 children treated with a mean cumulative anthracycline dose of 288 mg/m2 (median 280 mg/m2;Expand
  • 237
  • 6
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
BACKGROUND The use of anthracyclines is limited by the occurrence of cardiotoxicity. In an effort to prevent this cardiotoxicity, different anthracycline derivates have been studied. OBJECTIVES ToExpand
  • 107
  • 6
Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.
PURPOSE To determine the early and late cumulative incidence of anthracycline-induced clinical heart failure (A-CHF) after anthracycline therapy in childhood and to identify associated risk factors.Expand
  • 353
  • 5
Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.
BACKGROUND Anthracyclines are essential for the treatment of the children with cancer. We performed a systematic review to evaluate the existing evidence of the frequency and risk factors ofExpand
  • 205
  • 4